8-K: Olema & Pfizer Expand Breast Cancer Drug Collaboration

Olema Pharmaceuticals announced a new clinical trial agreement with Pfizer to evaluate palazestrant combined with atirmociclib for ER+/HER2metastatic breast cancer.

Summary

• Olema Pharmaceuticals, Inc. entered into a new clinical trial collaboration and supply agreement with Pfizer Inc. on September 2, 2025.
• The agreement focuses on a Phase 1b/2 study to evaluate the safety and combinability of Olema's palazestrant with Pfizer's investigational, highly selective-CDK4 inhibitor, atirmociclib.
• The study targets patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer.
• Pfizer will supply atirmociclib for the study, and Olema will lead the conduct of the study.
• Clinical data and inventions related to the combined use of atirmociclib and palazestrant will be jointly owned, with Olema retaining full global commercial and marketing rights to palazestrant.
• This marks Olema's second clinical trial agreement with Pfizer; the first was established in November 2020 to evaluate palazestrant with palbociclib (IBRANCE).
• The Phase 1b/2 study is anticipated to initiate in the second half of 2025 and will involve approximately 35 patients.
• Results from this study are intended to inform a potential pivotal Phase 3 trial for the novel combination in the frontline metastatic breast cancer setting.

Sentiment

Score: 7

Explanation: The new collaboration with Pfizer is a significant positive development, expanding the potential of Olema's lead candidate, palazestrant, and validating its therapeutic approach. It strengthens the development pipeline and market potential. However, it's still early-stage clinical development for this specific combination, and no immediate financial impact is detailed.

Positives

• Expanded collaboration with a major pharmaceutical company, Pfizer, which validates Olema's lead candidate, palazestrant.
• Potential for palazestrant to become a 'backbone endocrine therapy' for metastatic breast cancer through new combination therapies.
• Joint ownership of clinical data and inventions, while Olema retains full global commercial and marketing rights for palazestrant, preserving its long-term value.
• Advancement of palazestrant into a new combination study, potentially broadening its market and efficacy profile.
• The study aims to inform a potential pivotal Phase 3 trial, indicating a clear development pathway for the combination in the frontline setting.

Negatives

• No immediate financial metrics or revenue generation are detailed in this specific filing.
• The study is still in Phase 1b/2, meaning successful outcomes are not guaranteed, and further significant investment will be required for later phases.
• Reliance on Pfizer for the supply of atirmociclib introduces a dependency for the study's execution.

Risks

• Clinical trials are inherently uncertain, and the Phase 1b/2 study may not demonstrate the desired safety or combinability profile.
• Actual results, performance, or achievements could differ materially from forward-looking statements due to various risks and uncertainties.
• Risks and uncertainties are discussed in Olema's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and other SEC filings.
• Olema assumes no obligation to update forward-looking statements if actual results differ materially from those anticipated.

Future Outlook

Olema anticipates initiating the Phase 1b/2 study of palazestrant plus atirmociclib in approximately 35 patients in the second half of 2025. The results from this study are expected to inform a potential pivotal Phase 3 trial for this novel combination in the frontline metastatic breast cancer setting. Olema also expects to initiate its OPERA-02 ribociclib combination trial in frontline metastatic breast cancer this quarter, aiming to establish palazestrant as a potential backbone endocrine therapy and transform the metastatic breast cancer treatment paradigm.

Management Comments

• "We are excited to assess this combination in the clinic as we seek to establish palazestrant as a potential backbone endocrine therapy for metastatic breast cancer." Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology.
• "Based on the promising profiles of palazestrant and atirmociclib to date, we look forward to evaluating the potential of this novel combination and, if successful, advancing to a pivotal trial in the frontline setting." Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology.
• "With OPERA-01, our first pivotal study of palazestrant, underway and our OPERA-02 ribociclib combination trial in frontline metastatic breast cancer anticipated to initiate this quarter, we remain focused on achieving our goal of transforming the metastatic breast cancer treatment paradigm." Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology.

Industry Context

The collaboration between Olema and Pfizer for a novel combination therapy in ER+/HER2metastatic breast cancer aligns with a broader industry trend towards combination therapies to improve efficacy and overcome resistance in oncology. CDK4/6 inhibitors are a well-established class in this space, and combining a next-generation SERD/CERAN like palazestrant with a selective CDK4 inhibitor like atirmociclib represents an effort to enhance treatment options, particularly in the frontline setting where significant unmet needs remain for durable responses.

Comparison to Industry Standards

• The combination of a SERD/CERAN (palazestrant) with a CDK4 inhibitor (atirmociclib) is a common and promising strategy in ER+/HER2metastatic breast cancer, building on the success of combinations like fulvestrant with palbociclib (IBRANCE) or ribociclib (KISQALI).
• Pfizer's IBRANCE (palbociclib) is a market leader in CDK4/6 inhibition, and its continued investment in next-generation inhibitors like atirmociclib, combined with Olema's palazestrant, indicates a strategic focus on maintaining leadership in breast cancer treatment.
• The pursuit of a frontline metastatic breast cancer indication for this novel combination, following successful Phase 1b/2 results, positions it against established frontline regimens and other emerging therapies in a highly competitive landscape.

Stakeholder Impact

• Shareholders: Potential for increased long-term value due to expanded pipeline and validation from a major partner, but also continued clinical development risks.
• Patients: Potential for a new, more effective treatment option for ER+/HER2metastatic breast cancer.
• Employees: Continued focus on clinical development and potential for future growth.
• Pfizer: Strengthens its oncology pipeline with a promising combination therapy.

Next Steps

• Initiate the Phase 1b/2 study of palazestrant plus atirmociclib in approximately 35 patients in H2 2025.
• Initiate the OPERA-02 ribociclib combination trial in frontline metastatic breast cancer this quarter.
• Evaluate results from the Phase 1b/2 study to inform a potential pivotal Phase 3 trial for the palazestrant-atirmociclib combination.
• Continue the ongoing pivotal Phase 3 clinical trial, OPERA-01, for palazestrant as a single agent.

Key Dates

Recommendation

The new collaboration with Pfizer is a positive step, validating Olema's lead asset and expanding its potential market. However, the study is still in early phases, and significant clinical and regulatory hurdles remain. While the long-term outlook is improved, immediate catalysts for a 'buy' recommendation are limited, and the stock's performance will largely depend on future clinical data. A 'hold' position allows investors to monitor the progress of this and other ongoing trials without taking on additional risk at this stage.

Keywords

Olema Pharmaceuticals, Pfizer, Palazestrant, Atirmociclib, Breast Cancer, ER+/HER2-, Metastatic Breast Cancer, Clinical Trial, CDK4 Inhibitor, SERD, CERAN, Oncology